LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 20

Search options

  1. Article ; Online: Prevalence of potentially inappropriate medications among newly treated patients with type 2 diabetes in UK primary care.

    Faquetti, Maria Luisa / Frey, Géraldine / Stämpfli, Dominik / Weiler, Stefan / Burden, Andrea M

    British journal of clinical pharmacology

    2024  

    Abstract: Aims: The aim of this study was to estimate the prevalence of potentially inappropriate prescriptions (PIPs) in patients starting their first noninsulin antidiabetic treatment (NIAD) using two explicit process measures of the appropriateness of ... ...

    Abstract Aims: The aim of this study was to estimate the prevalence of potentially inappropriate prescriptions (PIPs) in patients starting their first noninsulin antidiabetic treatment (NIAD) using two explicit process measures of the appropriateness of prescribing in UK primary care, stratified by age and polypharmacy status.
    Methods: A descriptive cohort study between 2016 and 2019 was conducted to assess PIPs in patients aged ≥45 years at the start of their first NIAD, stratified by age and polypharmacy status. The American Geriatrics Society Beers criteria 2015 was used for older (≥65 years) patients and the Prescribing Optimally in Middle-age People's Treatments criteria was used for middle-aged (45-64 years) patients. Prevalence of overall PIPs and individual PIPs criteria was reported using the IQVIA Medical Research Data incorporating THIN, a Cegedim Database of anonymized electronic health records in the UK.
    Results: Among 28 604 patients initiating NIADs, 18 494 (64.7%) received polypharmacy. In older and middle-aged patients with polypharmacy, 39.6% and 22.7%, respectively, received ≥1 PIP. At the individual PIP level, long-term proton pump inhibitors (PPI) use was the most frequent PIP among older adults, and strong opioid without laxatives was the most frequent PIP in middle-aged patients with polypharmacy (11.1% and 4.1%, respectively).
    Conclusions: This study revealed that patients starting NIAD treatment receiving polypharmacy have the potential for pharmacotherapy optimization.
    Language English
    Publishing date 2024-02-26
    Publishing country England
    Document type Journal Article
    ZDB-ID 188974-6
    ISSN 1365-2125 ; 0306-5251 ; 0264-3774
    ISSN (online) 1365-2125
    ISSN 0306-5251 ; 0264-3774
    DOI 10.1111/bcp.16018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Hepatitis C virus screening in community pharmacies: results on feasibility from a Swiss pilot.

    Stämpfli, Dominik / Imfeld-Isenegger, Tamara Leila / Hersberger, Kurt E / Messerli, Markus

    BMC infectious diseases

    2023  Volume 23, Issue 1, Page(s) 384

    Abstract: Background: Hepatitis C virus (HCV) infections are a public health burden worldwide and often go undetected until sequelae develop. Offering HCV screening for the different vulnerable populations in community pharmacies could help prevent further ... ...

    Abstract Background: Hepatitis C virus (HCV) infections are a public health burden worldwide and often go undetected until sequelae develop. Offering HCV screening for the different vulnerable populations in community pharmacies could help prevent further undetected HCV infections. This pilot aimed to assess the feasibility and pharmacist acceptance of HCV rapid antibody saliva testing in community pharmacies.
    Methods: A structured pharmaceutical care intervention was developed that included addressing, informing, and screening clients, as well as referral and reporting to subsequent health care providers. Participating pharmacies from French-, German- and Italian-speaking parts of Switzerland were trained to provide this service to local vulnerable populations. Information on client recruitment, feasibility, and acceptability of HCV screening was collected.
    Results: Of 36 pharmacies initially recruited, 25 started the pilot and approached 435 clients, 145 of whom (33%) were interested in screening. Eight of these rapid antibody tests returned positive (prevalence rate: 5.5%). Facilitators were being able to offer a free rapid test (73%), followed by having training prior to the project (67%) and having a new service to offer (67%). The possibility of clients reacting dismissively (53%) and of unsettling clients (47%) were reported to be the main barriers.
    Conclusions: This pilot demonstrated the general feasibility of an HCV screening service with rapid antibody saliva testing in Swiss community pharmacies, which achieved a higher prevalence rate than national estimates. With appropriate communication training and remuneration, Swiss community pharmacies could be an important partner in implementing HCV elimination strategies.
    MeSH term(s) Humans ; Hepacivirus ; Pharmacies ; Feasibility Studies ; Switzerland ; Hepatitis C/diagnosis ; Hepatitis C/epidemiology ; Mass Screening/methods
    Language English
    Publishing date 2023-06-07
    Publishing country England
    Document type Journal Article
    ZDB-ID 2041550-3
    ISSN 1471-2334 ; 1471-2334
    ISSN (online) 1471-2334
    ISSN 1471-2334
    DOI 10.1186/s12879-023-08362-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: An explorative analysis of pharmacovigilance data of oxytocin and its analogue carbetocin, with a focus on haemodynamic adverse effects.

    Stämpfli, Dominik / Dommrich, Rebecca / Orbach-Zinger, Sharon / Burden, Andrea M / Heesen, Michael

    International journal of clinical pharmacy

    2023  Volume 45, Issue 4, Page(s) 922–928

    Abstract: Background: Oxytocin and its analogue carbetocin are uterotonics whose prophylactic use is recommended to prevent postpartum haemorrhage, which is one of the leading causes of maternal deaths worldwide. However, both drugs can cause specific adverse ... ...

    Abstract Background: Oxytocin and its analogue carbetocin are uterotonics whose prophylactic use is recommended to prevent postpartum haemorrhage, which is one of the leading causes of maternal deaths worldwide. However, both drugs can cause specific adverse effects and haemodynamic challenges.
    Aim: The aim of this work was to exploratively examine reports of adverse drug events of both drugs and to establish a comparative haemodynamic profile.
    Method: Using data extracted from the World Health Organization's pharmacovigilance database VigiBase, a descriptive analysis was performed of all reports for oxytocin and carbetocin as a suspected or interacting drug followed by a disproportionality analysis for haemodynamic events. Reporting odds ratios (ROR) of carbetocin for hypertension, hypotension, tachycardia, and bradycardia were calculated, with oxytocin-related reports serving as comparators.
    Results: Oxytocin and carbetocin were mentioned as suspected or interacting drugs in 11,258 and 374 reports, respectively. Resulting RORs for carbetocin were 3.45 (95%CI: 1.72-6.92) for hypertension, 2.65 (1.64-4.28) for hypotension, 2.84 (1.79-4.49) for tachycardia, and 2.00 (0.87-4.60) for bradycardia, when compared to oxytocin. Of 231 patients for whom oxytocin-related tachycardia was reported, 2.6% died, and of 91 patients for whom bradycardia was reported, 2.2% died. No deaths were reported with carbetocin for any of the haemodynamic adverse events.
    Conclusion: Compared to oxytocin, carbetocin showed an elevated reporting for adverse hypertension, hypotension, and tachycardia in pharmacovigilance data. Clinicians should be aware of their patients' individual susceptibility and the possibility of haemodynamic deterioration until causal inferences are possible.
    MeSH term(s) Female ; Humans ; Oxytocin/adverse effects ; Oxytocics ; Bradycardia/chemically induced ; Pharmacovigilance ; Drug-Related Side Effects and Adverse Reactions ; Hemodynamics ; Hypertension/chemically induced ; Hypotension/chemically induced
    Chemical Substances carbetocin (88TWF8015Y) ; Oxytocin (50-56-6) ; Oxytocics
    Language English
    Publishing date 2023-05-10
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2601204-2
    ISSN 2210-7711 ; 2210-7703 ; 0928-1231
    ISSN (online) 2210-7711
    ISSN 2210-7703 ; 0928-1231
    DOI 10.1007/s11096-023-01587-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance.

    Stämpfli, Dominik / Weiler, Stefan / Burden, Andrea M

    European child & adolescent psychiatry

    2020  Volume 30, Issue 7, Page(s) 1047–1058

    Abstract: For patients with attention deficit hyperactivity disorder and comorbid conduct-dissocial disorder, a combination therapy of the psychostimulant methylphenidate and the antipsychotic risperidone may be prescribed. Case reports describe the occurrence of ... ...

    Abstract For patients with attention deficit hyperactivity disorder and comorbid conduct-dissocial disorder, a combination therapy of the psychostimulant methylphenidate and the antipsychotic risperidone may be prescribed. Case reports describe the occurrence of movement disorders under this combination therapy, but clinical trials had limited power to detect these events. This study aimed (1) to summarise published case reports and (2) to analyse pharmacovigilance data consisting of adverse drug event reports to elucidate these reactions. PubMed, Embase, and APA PsycInfo were used to retrieve case reports. For the pharmacovigilance data, aggregated information on individual case safety reports (ICSRs) within the database of suspected adverse drug events by the WHO were analysed. ICSRs were assessed for disproportionality in reporting. Thirteen published case reports (62% male) on movement disorders were identified, with ages between 5 and 15 years. Seven reports (54%) described incidents when risperidone was tapered down or switched to methylphenidate. From the WHO, we identified 25,556 ICSRs (16,118 for methylphenidate, 8,614 for risperidone, and 824 for both). Of these, 953 (5.9%), 1356 (15.7%), and 159 (19.3%) ICSRs reported movement disorders in association with methylphenidate, risperidone or both, respectively. The analyses on disproportionality showed an increased number of ICSRs with movement disorders when the two drugs were coded in combination. The potential of movement disorders as adverse effects might be amplified when methylphenidate and risperidone are used in combination. The results from the literature underline the necessity of caution and patient monitoring when risperidone dosing is modified during methylphenidate therapy.
    MeSH term(s) Attention Deficit Disorder with Hyperactivity/drug therapy ; Combined Modality Therapy/adverse effects ; Comorbidity ; Conduct Disorder/drug therapy ; Databases, Factual ; Humans ; Methylphenidate/adverse effects ; Methylphenidate/therapeutic use ; Movement Disorders/epidemiology ; Pharmacovigilance ; Risperidone/adverse effects ; Risperidone/therapeutic use ; World Health Organization
    Chemical Substances Methylphenidate (207ZZ9QZ49) ; Risperidone (L6UH7ZF8HC)
    Language English
    Publishing date 2020-07-03
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 1118299-4
    ISSN 1435-165X ; 1018-8827 ; 1433-5719
    ISSN (online) 1435-165X
    ISSN 1018-8827 ; 1433-5719
    DOI 10.1007/s00787-020-01589-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Assessment of minor health disorders with decision tree-based triage in community pharmacies.

    Stämpfli, Dominik / Winkler, Birgit A / Vilei, Simona Berardi / Burden, Andrea M

    Research in social & administrative pharmacy : RSAP

    2021  Volume 18, Issue 5, Page(s) 2867–2873

    Abstract: Background: Triaging in community pharmacies can lower the burden of minor health disorders on other primary health care settings. The netCare service, introduced in 2012 by the Swiss association of pharmacists, provides community pharmacists with 27 ... ...

    Abstract Background: Triaging in community pharmacies can lower the burden of minor health disorders on other primary health care settings. The netCare service, introduced in 2012 by the Swiss association of pharmacists, provides community pharmacists with 27 decision trees for the triage of minor health disorders.
    Objectives: (1) to describe the utilization and symptom resolving rate of decision trees in community pharmacies; (2) to identify the need for additional decision trees.
    Methods: A descriptive, explorative analysis was conducted of netCare consultations between January 2019 and March 2020, as documented in phS-net, a service platform for public pharmacies. Client characteristics, weekdays, recommended course of action, availability of a general practitioner, and hypothetical course of action if netCare would not have been available were investigated. Follow-up information was assessed for resolution of symptoms and prevention of needing additional services. Data from consultations with empty assessment forms were used to identify minor health disorders in need of an additional decision tree.
    Results: Information on 4256 performed netCare consultations were identified over a 14-month observation period, resulting in an average of 284 decision tree consultations per month in Switzerland. Customers were mainly female (n = 3253, 76.4%) with a mean age of 40.7 years (±18.5 years). Cystitis (39.5%), conjunctivitis (19.5%), and pharyngitis (10.9%) were the primary reasons for consultation. Minor health disorders were managed by pharmacists themselves (88.2%) and achieved a resolution rate of 84.7%. Eyelid inflammations were identified as in need for an additional decision tree.
    Conclusion: Pharmacist-led structured triaging services in Switzerland led to an 84.7% resolution rate of minor health disorders, thereby identifying the potential for pharmacists to minimize the demand on other primary health care providers.
    MeSH term(s) Adult ; Community Pharmacy Services ; Decision Trees ; Female ; Humans ; Pharmacies ; Pharmacists ; Triage
    Language English
    Publishing date 2021-07-03
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2192059-X
    ISSN 1934-8150 ; 1551-7411
    ISSN (online) 1934-8150
    ISSN 1551-7411
    DOI 10.1016/j.sapharm.2021.07.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Lehrveranstaltung zu interprofessionellen Versorgungsketten in der Schweiz.

    Schlegel, Claudia / Stämpfli, Dominik / Kut, Elvan / Mang, Georg / Moser, Toni / Useini, Mirdita / Goldhahn, Jörg

    Praxis

    2022  Volume 110, Issue 1, Page(s) 26–31

    Abstract: Teaching Interprofessional Patient Pathways in Medical Education in Switzerland - A Collaboration of Multiple ... ...

    Title translation Teaching Interprofessional Patient Pathways in Medical Education in Switzerland - A Collaboration of Multiple Players.
    Abstract Teaching Interprofessional Patient Pathways in Medical Education in Switzerland - A Collaboration of Multiple Players
    MeSH term(s) Curriculum ; Education, Medical ; Humans ; Medicine ; Students, Medical ; Switzerland
    Language German
    Publishing date 2022-01-04
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 209026-0
    ISSN 1661-8165 ; 1661-8157 ; 0369-8394
    ISSN (online) 1661-8165
    ISSN 1661-8157 ; 0369-8394
    DOI 10.1024/1661-8157/a003770
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Renal ischemic adverse drug events related to tranexamic acid in women of child-bearing age: an analysis of pharmacovigilance data.

    Stämpfli, Dominik / Weiler, Stefan / Weiniger, Carolyn F / Burden, Andrea M / Heesen, Michael

    European journal of clinical pharmacology

    2020  Volume 77, Issue 6, Page(s) 913–919

    Abstract: Purpose: In response to a large trial, the World Health Organization broadened their recommendation on tranexamic acid to be used for post-partum hemorrhage. A 2013 French periodic safety update report warned of an abnormally high rate of renal cortical ...

    Abstract Purpose: In response to a large trial, the World Health Organization broadened their recommendation on tranexamic acid to be used for post-partum hemorrhage. A 2013 French periodic safety update report warned of an abnormally high rate of renal cortical necrosis associated with tranexamic acid and other drugs for severe post-partum hemorrhage. We aimed to identify the reporting incidence of adverse thrombo-embolic events among women in child-bearing age who received tranexamic acid, with a focus on renal vascular and ischemic conditions.
    Methods: We analyzed individual case safety reports (ICSRs) on renal vascular and ischemic conditions, pulmonary thrombotic and embolic conditions, and peripheral embolism and thrombosis from the database of the World Health Organization - Uppsala Monitoring Centre (WHO-UMC). ICSRs were restricted to reports including tranexamic acid as a suspected drug, sex reported as female, and reported age between 18 and 44 years. Reporting odds ratios (RORs) and 95% confidence intervals (95% CIs) were calculated by comparing ICSRs on tranexamic acid to all other drugs in VigiBase.
    Results: Within 2245 included ICSRs on tranexamic acid, we identified 29 reports of adverse renal vascular and ischemic conditions, 42 reports of pulmonary thrombotic and embolic conditions, and 41 reports of peripheral embolism and thrombosis. RORs were statistically significant by 32.6-fold (32.62, 95% CI: 22.50-47.29), 2.5-fold (2.52, 95% CI: 1.85-3.42), and 2.7-fold (2.67, 95% CI: 1.96-3.64), respectively, when compared to any other drug within VigiBase.
    Conclusion: Tranexamic acid might bear an increased risk for renal ischemic adverse drug events in women of child-bearing age.
    MeSH term(s) Adolescent ; Adult ; Antifibrinolytic Agents/administration & dosage ; Antifibrinolytic Agents/adverse effects ; Databases, Factual ; Embolism/chemically induced ; Female ; Humans ; Ischemia/chemically induced ; Kidney Diseases/chemically induced ; Pharmacovigilance ; Postpartum Hemorrhage/prevention & control ; Thrombosis/chemically induced ; Thrombosis/prevention & control ; Tranexamic Acid/administration & dosage ; Tranexamic Acid/adverse effects ; World Health Organization ; Young Adult
    Chemical Substances Antifibrinolytic Agents ; Tranexamic Acid (6T84R30KC1)
    Language English
    Publishing date 2020-12-19
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 121960-1
    ISSN 1432-1041 ; 0031-6970
    ISSN (online) 1432-1041
    ISSN 0031-6970
    DOI 10.1007/s00228-020-03064-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Übersicht. Psychiatrische Patienten fragen ihren Arzt und Apotheker - wie kann die ambulante Versorgung optimiert werden?

    Baumann, Pierre / Hahn, Martina / Roll, Sibylle C. / Stämpfli, Dominik

    Psychopharmakotherapie

    2020  Volume 27, Issue 6, Page(s) 270

    Language German
    Document type Article
    ZDB-ID 1196510-1
    ISSN 0944-6877
    Database Current Contents Medicine

    More links

    Kategorien

  9. Article: Community Pharmacist-Administered COVID-19 Vaccinations: A Pilot Customer Survey on Satisfaction and Motivation to Get Vaccinated.

    Stämpfli, Dominik / Martinez-De la Torre, Adrian / Simi, Elodie / Du Pasquier, Sophie / Berger, Jérôme / Burden, Andrea M

    Vaccines

    2021  Volume 9, Issue 11

    Abstract: In response to the coronavirus disease 2019 (COVID-19) pandemic, Swiss health authorities approved and ordered two mRNA vaccines in 2021. The canton of Zurich was the second in Switzerland to allow community pharmacists to administer the COVID-19 mRNA ... ...

    Abstract In response to the coronavirus disease 2019 (COVID-19) pandemic, Swiss health authorities approved and ordered two mRNA vaccines in 2021. The canton of Zurich was the second in Switzerland to allow community pharmacists to administer the COVID-19 mRNA Vaccine Moderna to the adult population. We aimed to pilot a customer satisfaction questionnaire regarding COVID-19 vaccinations in Zurich pharmacies. Questions focused on satisfaction with different aspects of the service, motivation for getting the vaccination, and reasons for being vaccinated in a pharmacy. Zurich pharmacies administered 68,169 COVID-19 doses until June 2021, and 421 questionnaires were filled. Respondents' mean age was 43.5 (±13.2) years, with 42.3% reporting being women and 46.1% being men. Of the 372 complete questionnaires, 98.7% of the respondents would have recommended the service to others. High levels of satisfaction were reported concerning pre-vaccination discussion (98.9%), pharmacies' information level on COVID-19 vaccines (98.9%), general comfort with receiving the vaccination in a pharmacy (99.5%), injection technique (99.2%), and premises used (98.1%). Most respondents (57.3%) would have had the option of another vaccination provider, but the pharmacies were chosen for their opening hours, ease of access, and perceived trust. The availability of pharmacist-administered services may be an important contributor to a successful vaccination programme in Switzerland.
    Language English
    Publishing date 2021-11-14
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2703319-3
    ISSN 2076-393X
    ISSN 2076-393X
    DOI 10.3390/vaccines9111320
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: External validation of the PAR-Risk Score to assess potentially avoidable hospital readmission risk in internal medicine patients.

    Higi, Lukas / Lisibach, Angela / Beeler, Patrick E / Lutters, Monika / Blanc, Anne-Laure / Burden, Andrea M / Stämpfli, Dominik

    PloS one

    2021  Volume 16, Issue 11, Page(s) e0259864

    Abstract: Background: Readmission prediction models have been developed and validated for targeted in-hospital preventive interventions. We aimed to externally validate the Potentially Avoidable Readmission-Risk Score (PAR-Risk Score), a 12-items prediction model ...

    Abstract Background: Readmission prediction models have been developed and validated for targeted in-hospital preventive interventions. We aimed to externally validate the Potentially Avoidable Readmission-Risk Score (PAR-Risk Score), a 12-items prediction model for internal medicine patients with a convenient scoring system, for our local patient cohort.
    Methods: A cohort study using electronic health record data from the internal medicine ward of a Swiss tertiary teaching hospital was conducted. The individual PAR-Risk Score values were calculated for each patient. Univariable logistic regression was used to predict potentially avoidable readmissions (PARs), as identified by the SQLape algorithm. For additional analyses, patients were stratified into low, medium, and high risk according to tertiles based on the PAR-Risk Score. Statistical associations between predictor variables and PAR as outcome were assessed using both univariable and multivariable logistic regression.
    Results: The final dataset consisted of 5,985 patients. Of these, 340 patients (5.7%) experienced a PAR. The overall PAR-Risk Score showed rather poor discriminatory power (C statistic 0.605, 95%-CI 0.575-0.635). When using stratified groups (low, medium, high), patients in the high-risk group were at statistically significant higher odds (OR 2.63, 95%-CI 1.33-5.18) of being readmitted within 30 days compared to low risk patients. Multivariable logistic regression identified previous admission within six months, anaemia, heart failure, and opioids to be significantly associated with PAR in this patient cohort.
    Conclusion: This external validation showed a limited overall performance of the PAR-Risk Score, although higher scores were associated with an increased risk for PAR and patients in the high-risk group were at significantly higher odds of being readmitted within 30 days. This study highlights the importance of externally validating prediction models.
    MeSH term(s) Adult ; Aged ; Algorithms ; Cohort Studies ; Electronic Health Records ; Female ; Forecasting/methods ; Hospitalization/trends ; Humans ; Internal Medicine ; Logistic Models ; Male ; Middle Aged ; Patient Readmission/statistics & numerical data ; Patient Readmission/trends ; Risk Factors ; Switzerland
    Language English
    Publishing date 2021-11-23
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0259864
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top